share_log

Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5

Benzinga ·  Nov 28, 2024 01:34  · Ratings

Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Outperform and lowers the price target from $3 to $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment